ACTION3 – Phase 3 study of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS)

https://storage.unitedwebnetwork.com/files/184/fe2de80e6d276e2217daa82a156b73a4.pdf

Jonathon Barratt jb81@leicester.ac.uk University of Leicester Dept Cardiovascular Sciences Leicester

Anant Desai a.desai@amicisresearch.com Amicis Research Centre Nephrology California

Alessia Fornoni jxg1536@med.miami.edu University of Miami Peggy and Harold Katz Family Drug Discovery Center Miami

Lesley Inker Lesley.Inker@tuftsmedicine.org Tufts University Kidney and Blood Pressure Center Boston

Irene de Lourdes Noronha irenenor@usp.br Hospital das Clínicas da Faculdade de Medicina da USP Nephrology Sao Paulo

Alejandra Quevedo alejandra.s.quevedo@gmail.com Centro Medico Dra Maffei - Investigación Clínica Aplicad Nephrology Buenos Aires

Robert Shepherd robert.shepherd@dimerix.com Dimerix Bioscience Pty Ltd BD Fitzroy

Alisha Smith alisha.smith@dimerix.com Dimerix Bioscience Pty Ltd Clinical Fitzroy

Hernan Trimarchi htrimarchi@hotmail.com Hospital Britáinico de Buenos Aires Nephrology Dept Buenos Aires

Lucila Valente lucilamvalente@gmai.com Hospital das Clinicas da UFPE Nephrology Dept RECIFE

Mona Wahba mona.wahba@nhs.net St Heliers Hospital Nephrology Dept London

Muh Geot Wong muhgeot.wong@sydney.edu.au Concord Repatriation General Hospital Renal Medicine Concord

Hiddo Lambers Heerspink h.j.lambers.heerspink@umcg.nl University Medical Center Groningen Department of Clinical Pharmacy and Pharmacology Groningen